Pub Date : 1999-01-01DOI: 10.5649/JJPHCS1975.25.28
K. Masaki, K. Ueno, M. Tsuji, K. Hiraki, M. Takada, S. Kamakura, M. Shibakawa
A simple reverse-phase high-performance liquid chromatographic (HPLC) assay for the measurement of amiodarone and its metabolite, desethylamiodarone in the serum was established. The ODS-2 column was used and the absorbance of the effluent from the column at 254 nm was measured. The standard curves for amiodarone and desethylamiodarone were linear up to 5μg/ml. The coefficent of variation (CV) was within 10% at a concentration of 100 ng/ml, and the CV of the intra-and interday variation was within 10% at concentrations of 0.25, 0.5 and 1μg/ml, respectively. These results suggest that the limit of detection is 100 ng/ml for amiodarone and desethylamiodarone, and this assay is thus considered to be a reliable method in clinical practice. On the other hand, the serum amiodarone and desethylamiodarone concentrations were measured in 10 inpatients who received amiodarone for at least 1 month. No significant correlation was observed between the doses and serum drug concentrations. There findings therefore suggest that TDM (Therapeutic Drug Monitoring) should be performed on anyone taking amiodarone.
{"title":"A Simple Assay for Amiodarone and Desethylamiodarone and its Clinical Application.","authors":"K. Masaki, K. Ueno, M. Tsuji, K. Hiraki, M. Takada, S. Kamakura, M. Shibakawa","doi":"10.5649/JJPHCS1975.25.28","DOIUrl":"https://doi.org/10.5649/JJPHCS1975.25.28","url":null,"abstract":"A simple reverse-phase high-performance liquid chromatographic (HPLC) assay for the measurement of amiodarone and its metabolite, desethylamiodarone in the serum was established. The ODS-2 column was used and the absorbance of the effluent from the column at 254 nm was measured. The standard curves for amiodarone and desethylamiodarone were linear up to 5μg/ml. The coefficent of variation (CV) was within 10% at a concentration of 100 ng/ml, and the CV of the intra-and interday variation was within 10% at concentrations of 0.25, 0.5 and 1μg/ml, respectively. These results suggest that the limit of detection is 100 ng/ml for amiodarone and desethylamiodarone, and this assay is thus considered to be a reliable method in clinical practice. On the other hand, the serum amiodarone and desethylamiodarone concentrations were measured in 10 inpatients who received amiodarone for at least 1 month. No significant correlation was observed between the doses and serum drug concentrations. There findings therefore suggest that TDM (Therapeutic Drug Monitoring) should be performed on anyone taking amiodarone.","PeriodicalId":14621,"journal":{"name":"Japanese Journal of Hospital Pharmacy","volume":"172 1","pages":"28-33"},"PeriodicalIF":0.0,"publicationDate":"1999-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76748366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1999-01-01DOI: 10.5649/JJPHCS1975.25.450
F. Ojima, T. Toyoguchi, T. Syoji, Y. Nakagawa
In order to investigate the pharmaceutical equivalency of four propentofylline enteric-coated tablets (a pioneer preparation and 3 generic preparations), a quantitative analysis, disintegration testing and dissolution testing were all performed to evaluate them.The mean contents of propentofylline in each preparation ranged from 96 to 102%. All of the tested materials conformed to the findings for the disintegration test for enteric-coated articles in the thirteeth revised edition of Japanese Pharmacopoeia (JP). However, at the end of the disintegration test with the 1st test medium (pH 1.2), swelling was observed in one or more of the 6 tested tablets for two of the generic preparations. Although no release of propentofylline was recognized, the core of the swollen tablets had completely disintegrated inside the enteric coating film in one of the two swollen generic preparations. When doing the same test aften placing the disks in gastric fluid, the propentofylline finally dissolved in the medium after 120 min. The dissolution test was performed with a paddle (100 rpm) according to JP using a 0.05 M phosphate buffer at pHs of 6.5 and 7.2. The dissolutions were complete in less than 60 min at both pHs, and they were faster at pH 7.2 for all preparations. However, the dissolution was significantly delayed, and the 75% dissolution time was also significantly prolonged for one of the three generic preparations at both pHs when compared to the other preparations.All of the propentofylline enteric-coated preparations were acceptable based on the JP criteria, however, the pharmaceutical equivalency of the generic preparations to the pioneer preparation heve not yet been obtained. As a result, the changes between generic preparations and pioneer preparations are therefore considered to be considerable, especially ragarding enteric coated preparations
{"title":"Investigation of Pharmaceutical Equivalency in Pioneer and Generic Enteric-Coated Tablets.","authors":"F. Ojima, T. Toyoguchi, T. Syoji, Y. Nakagawa","doi":"10.5649/JJPHCS1975.25.450","DOIUrl":"https://doi.org/10.5649/JJPHCS1975.25.450","url":null,"abstract":"In order to investigate the pharmaceutical equivalency of four propentofylline enteric-coated tablets (a pioneer preparation and 3 generic preparations), a quantitative analysis, disintegration testing and dissolution testing were all performed to evaluate them.The mean contents of propentofylline in each preparation ranged from 96 to 102%. All of the tested materials conformed to the findings for the disintegration test for enteric-coated articles in the thirteeth revised edition of Japanese Pharmacopoeia (JP). However, at the end of the disintegration test with the 1st test medium (pH 1.2), swelling was observed in one or more of the 6 tested tablets for two of the generic preparations. Although no release of propentofylline was recognized, the core of the swollen tablets had completely disintegrated inside the enteric coating film in one of the two swollen generic preparations. When doing the same test aften placing the disks in gastric fluid, the propentofylline finally dissolved in the medium after 120 min. The dissolution test was performed with a paddle (100 rpm) according to JP using a 0.05 M phosphate buffer at pHs of 6.5 and 7.2. The dissolutions were complete in less than 60 min at both pHs, and they were faster at pH 7.2 for all preparations. However, the dissolution was significantly delayed, and the 75% dissolution time was also significantly prolonged for one of the three generic preparations at both pHs when compared to the other preparations.All of the propentofylline enteric-coated preparations were acceptable based on the JP criteria, however, the pharmaceutical equivalency of the generic preparations to the pioneer preparation heve not yet been obtained. As a result, the changes between generic preparations and pioneer preparations are therefore considered to be considerable, especially ragarding enteric coated preparations","PeriodicalId":14621,"journal":{"name":"Japanese Journal of Hospital Pharmacy","volume":"178 3 1","pages":"450-459"},"PeriodicalIF":0.0,"publicationDate":"1999-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73611794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1999-01-01DOI: 10.5649/JJPHCS1975.25.393
B. Hino, Y. Kurosaki, K. Yamauchi, K. Kamiya, H. Araki, Y. Gomita, N. Goto, M. Masada, H. Kawasaki
As DDS drugs with various drug delivery functions are often prescribed under in conbination with a widerange of concurrent drug therapies, drug information closely related to its clinical usage is required to guarantee the appropriate multiple pharmaceutical functions of DDS drugs: We surveyed the actual concurrent therapy of lipo-PGE1 (Palux® inj. and Liple®), a targeting-type DDS, with various aqueous infusions at both Okayama University Hospital and Fukui Medical School Hospital. The term of the survey, which was done by evaluating the prescription records, and the total number of prescriptions were 14 months and 1, 005 prescriptions, respectively. Lipo-PGE1 was scarcely administered without any concurrently prescribed infusions. Although lipo-PGE1 was mostly diluted with Glucose Injection or Isotonic Sodium Chloride Solution, some electrolyte infusions were also concurrently prescribed with Lipo-PGE1 in some cases. The magnification of the dilution and the administration route seemed to be related each other. The data revealed in this report ave considered to be useful for a clinical usage-based assessment system to obtain further information guaranteeing the drug delivery function of Lipo-PGE1 from both a pharmaceutical and pharmacodynamic viewpoint one word.
{"title":"Clinical Use of Drug Delivery Systems: Prescription Survey on Clinical Use of PGE1 in Lipid Emulsions with Aqueous Infusions.","authors":"B. Hino, Y. Kurosaki, K. Yamauchi, K. Kamiya, H. Araki, Y. Gomita, N. Goto, M. Masada, H. Kawasaki","doi":"10.5649/JJPHCS1975.25.393","DOIUrl":"https://doi.org/10.5649/JJPHCS1975.25.393","url":null,"abstract":"As DDS drugs with various drug delivery functions are often prescribed under in conbination with a widerange of concurrent drug therapies, drug information closely related to its clinical usage is required to guarantee the appropriate multiple pharmaceutical functions of DDS drugs: We surveyed the actual concurrent therapy of lipo-PGE1 (Palux® inj. and Liple®), a targeting-type DDS, with various aqueous infusions at both Okayama University Hospital and Fukui Medical School Hospital. The term of the survey, which was done by evaluating the prescription records, and the total number of prescriptions were 14 months and 1, 005 prescriptions, respectively. Lipo-PGE1 was scarcely administered without any concurrently prescribed infusions. Although lipo-PGE1 was mostly diluted with Glucose Injection or Isotonic Sodium Chloride Solution, some electrolyte infusions were also concurrently prescribed with Lipo-PGE1 in some cases. The magnification of the dilution and the administration route seemed to be related each other. The data revealed in this report ave considered to be useful for a clinical usage-based assessment system to obtain further information guaranteeing the drug delivery function of Lipo-PGE1 from both a pharmaceutical and pharmacodynamic viewpoint one word.","PeriodicalId":14621,"journal":{"name":"Japanese Journal of Hospital Pharmacy","volume":"38 1","pages":"393-398"},"PeriodicalIF":0.0,"publicationDate":"1999-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84308785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1999-01-01DOI: 10.5649/JJPHCS1975.25.603
A. Takahashi, K. Saito, Y. Takizawa, R. Murata
We examined the pharmacokinetics of theophylline in two types of experimental diabetic rats, streptozotocin-induced diabetic (STZ) rats with insulin dependent diabetes mellitus, and a genetic model of non-obese Goto-Kakizaki (GK) rats with non insulin dependent diabetes mellitus. After the rats were administered theophylline either intravenously or orally plasma was taken for a pharmacokinetic study. There were no significant differences in the pharmacokinetics of theophylline in the STZ rats compared with those of the controls. On the other hand, a delayed elimination process and absorption rate of theophylline were observed in GK rats in comparison to those of the controls. There findings suggest that two different phamacokinetics of theophylline exist depending on the two types of diabetic rats.
{"title":"Effect of Diabetes on Theophylline Disposition in the Rat.","authors":"A. Takahashi, K. Saito, Y. Takizawa, R. Murata","doi":"10.5649/JJPHCS1975.25.603","DOIUrl":"https://doi.org/10.5649/JJPHCS1975.25.603","url":null,"abstract":"We examined the pharmacokinetics of theophylline in two types of experimental diabetic rats, streptozotocin-induced diabetic (STZ) rats with insulin dependent diabetes mellitus, and a genetic model of non-obese Goto-Kakizaki (GK) rats with non insulin dependent diabetes mellitus. After the rats were administered theophylline either intravenously or orally plasma was taken for a pharmacokinetic study. There were no significant differences in the pharmacokinetics of theophylline in the STZ rats compared with those of the controls. On the other hand, a delayed elimination process and absorption rate of theophylline were observed in GK rats in comparison to those of the controls. There findings suggest that two different phamacokinetics of theophylline exist depending on the two types of diabetic rats.","PeriodicalId":14621,"journal":{"name":"Japanese Journal of Hospital Pharmacy","volume":"193 1","pages":"603-607"},"PeriodicalIF":0.0,"publicationDate":"1999-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80716966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1999-01-01DOI: 10.5649/jjphcs1975.25.176
Y. Arai, T. Nakane, A. Kubota, N. Mizushima, T. Shibata
Sodium Ferrous Citrate formulatio, Ferromia®granule was originally supplied as film-coated granules. However, some problems have been pointed out with this formulation regarding awkwardness in handling and unpleasantness during consumption.Therefore, corrigent was added while the film conting was removed in order to improve it.We investigated influence of changing the formilative method, and carry out the incompatibility test and hygroscopic test on 29 powders which can be admixed together. Furthermore, we also carried out a ferrous ion dissolution test on 11 powders which are likely to have an ionic interaction with iron. As a result, the modified granuls were incompatible when combined with ascorbic acid powder, Cinal ®granule, sodium bicarbonate and fblic acid powder (10%).The modified granules demonstrated no water-vapor sorption at 25°C, 75% RH at 30 days. Hygroscopicity was not considered to be related to incompatibility, and no noticeable difference was found due to the modification of the formulation.In the compounding the sample, dissolution property demonstrated only a slight difference in the ferrous ion elution.
{"title":"Compatibility of Sodium Ferrous Citrate Improved-Granules in Combination with Other Preparations.","authors":"Y. Arai, T. Nakane, A. Kubota, N. Mizushima, T. Shibata","doi":"10.5649/jjphcs1975.25.176","DOIUrl":"https://doi.org/10.5649/jjphcs1975.25.176","url":null,"abstract":"Sodium Ferrous Citrate formulatio, Ferromia®granule was originally supplied as film-coated granules. However, some problems have been pointed out with this formulation regarding awkwardness in handling and unpleasantness during consumption.Therefore, corrigent was added while the film conting was removed in order to improve it.We investigated influence of changing the formilative method, and carry out the incompatibility test and hygroscopic test on 29 powders which can be admixed together. Furthermore, we also carried out a ferrous ion dissolution test on 11 powders which are likely to have an ionic interaction with iron. As a result, the modified granuls were incompatible when combined with ascorbic acid powder, Cinal ®granule, sodium bicarbonate and fblic acid powder (10%).The modified granules demonstrated no water-vapor sorption at 25°C, 75% RH at 30 days. Hygroscopicity was not considered to be related to incompatibility, and no noticeable difference was found due to the modification of the formulation.In the compounding the sample, dissolution property demonstrated only a slight difference in the ferrous ion elution.","PeriodicalId":14621,"journal":{"name":"Japanese Journal of Hospital Pharmacy","volume":"11 1","pages":"176-186"},"PeriodicalIF":0.0,"publicationDate":"1999-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82525794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1999-01-01DOI: 10.5649/JJPHCS1975.25.40
Y. Wakiya, A. Saiki, N. Kondou, M. Masada
We investigated the stability of Vitamins in a total parenteral nutrition (TPN) solution. We compared examinations at the same clinical site at two different dosage periods for the administration of Vitamins (daytime and nighttime) with the finding of a basic examination. We thus found the stability in most instances to be the same as for the basic examination of stability in numerous Vitamins reports (effect of light and temperature, trace elements, sodium sulfite). At on clinical site during the different dosage periods, the dosage at nighttime was found to be better than that observed in the daytime. We consider this influence on stability of the Vitamins to be related to the alteration of the quantity of light during the daytime. These findings suggested that the addition of Vitamins to TPN solutions should therefore be avoided whenever possible during daytime administration.
{"title":"Stability of Vitamins in the TPN Mixture at a Clinical Site.","authors":"Y. Wakiya, A. Saiki, N. Kondou, M. Masada","doi":"10.5649/JJPHCS1975.25.40","DOIUrl":"https://doi.org/10.5649/JJPHCS1975.25.40","url":null,"abstract":"We investigated the stability of Vitamins in a total parenteral nutrition (TPN) solution. We compared examinations at the same clinical site at two different dosage periods for the administration of Vitamins (daytime and nighttime) with the finding of a basic examination. We thus found the stability in most instances to be the same as for the basic examination of stability in numerous Vitamins reports (effect of light and temperature, trace elements, sodium sulfite). At on clinical site during the different dosage periods, the dosage at nighttime was found to be better than that observed in the daytime. We consider this influence on stability of the Vitamins to be related to the alteration of the quantity of light during the daytime. These findings suggested that the addition of Vitamins to TPN solutions should therefore be avoided whenever possible during daytime administration.","PeriodicalId":14621,"journal":{"name":"Japanese Journal of Hospital Pharmacy","volume":"45 1","pages":"40-47"},"PeriodicalIF":0.0,"publicationDate":"1999-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80960142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1999-01-01DOI: 10.5649/JJPHCS1975.25.53
Mariko Asahi, Noriaki Kakimoto, J. Nishigami, R. Matsushita, F. Ichimura
The compilation of a Problem List for certain problems regarding drug therapy obtained through a clinical pharmacy service is useful for detecting and preventing any adverse drug reactions or potential problems in clinical practice. Such useful information is not available many other pharmacists in Japan. We tried to develop a database and a software program for such a Problem List based on the pharmaceutical care records at our hospital according to our proposed format. This database consists of 771 data which can be cross-referenced to diseases, drug names and clinical divisions, respectively. Moreover, we can statistically evaluate the Drug Information contents by pharmacists using this database. We here in propose that all pharmacists in Japan carefully preserve their pharmaceutical care records based on our format and so that all may use the database jointly.
{"title":"Development and Utilization of the Database of Problem List from Pharmaceutical Care Records Concerned with Problems and Assessments on Pharmacotherapy in Wards. Proposal to Use and Develop Jointly the Database of Problem List from Pharmaceutical Care Records.","authors":"Mariko Asahi, Noriaki Kakimoto, J. Nishigami, R. Matsushita, F. Ichimura","doi":"10.5649/JJPHCS1975.25.53","DOIUrl":"https://doi.org/10.5649/JJPHCS1975.25.53","url":null,"abstract":"The compilation of a Problem List for certain problems regarding drug therapy obtained through a clinical pharmacy service is useful for detecting and preventing any adverse drug reactions or potential problems in clinical practice. Such useful information is not available many other pharmacists in Japan. We tried to develop a database and a software program for such a Problem List based on the pharmaceutical care records at our hospital according to our proposed format. This database consists of 771 data which can be cross-referenced to diseases, drug names and clinical divisions, respectively. Moreover, we can statistically evaluate the Drug Information contents by pharmacists using this database. We here in propose that all pharmacists in Japan carefully preserve their pharmaceutical care records based on our format and so that all may use the database jointly.","PeriodicalId":14621,"journal":{"name":"Japanese Journal of Hospital Pharmacy","volume":"4 1","pages":"53-59"},"PeriodicalIF":0.0,"publicationDate":"1999-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87043808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1999-01-01DOI: 10.5649/JJPHCS1975.25.440
Y. Koike, K. Uno, Manabu Abe, M. Tsugita, M. Tobita, K. Kajiwara, K. Toyama, H. Kawase, N. Yohkoh, Mayumi Sasahara, Miho Takahashi, K. Ono, Youko Sutoh, S. Maruyama, Kazuhiko Nagai
{"title":"Questionnaire Survey about the Side Effects of Drugs in the Multiple Medical Institutions.","authors":"Y. Koike, K. Uno, Manabu Abe, M. Tsugita, M. Tobita, K. Kajiwara, K. Toyama, H. Kawase, N. Yohkoh, Mayumi Sasahara, Miho Takahashi, K. Ono, Youko Sutoh, S. Maruyama, Kazuhiko Nagai","doi":"10.5649/JJPHCS1975.25.440","DOIUrl":"https://doi.org/10.5649/JJPHCS1975.25.440","url":null,"abstract":"","PeriodicalId":14621,"journal":{"name":"Japanese Journal of Hospital Pharmacy","volume":"28 1","pages":"440-449"},"PeriodicalIF":0.0,"publicationDate":"1999-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90621098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1999-01-01DOI: 10.5649/JJPHCS1975.25.690
N. Takami, Ayumi Sakiya, K. Moriwaki, Masahiro Tamasiro
Switch OTC preparations of H2-receptor antagonists have been marketed since September 1997, which causes concern about the possible concomitant use with H2-receptor antagonists while the patient does not know that they are from the same drug class.We conducted a telephone-interview survey of patients awareness of drug information leaflets on switch OTC preparations of H2-receptor antagonists including precautions for use and adverse drug reactions in 203 patients who were taking ranitidine.Of the 203 patients, 16 (7.9%) purchased OTC preparations including cold remedy and gastric drugs. Of the 203 patients, 164 (80.8%) replied that they did not know about the selling of switch OTC preparations, because, for example, they were aware of their commercial message but did not know that they were from the same class of drug as ranitidine.Twenty-three (11.3%) of the 203 patients also received medication from other hospital (s), although type of drugs were not known.
{"title":"Survey of Drug Information Leaflet in Ranitidine Use for Outpatients. Switch OTC.","authors":"N. Takami, Ayumi Sakiya, K. Moriwaki, Masahiro Tamasiro","doi":"10.5649/JJPHCS1975.25.690","DOIUrl":"https://doi.org/10.5649/JJPHCS1975.25.690","url":null,"abstract":"Switch OTC preparations of H2-receptor antagonists have been marketed since September 1997, which causes concern about the possible concomitant use with H2-receptor antagonists while the patient does not know that they are from the same drug class.We conducted a telephone-interview survey of patients awareness of drug information leaflets on switch OTC preparations of H2-receptor antagonists including precautions for use and adverse drug reactions in 203 patients who were taking ranitidine.Of the 203 patients, 16 (7.9%) purchased OTC preparations including cold remedy and gastric drugs. Of the 203 patients, 164 (80.8%) replied that they did not know about the selling of switch OTC preparations, because, for example, they were aware of their commercial message but did not know that they were from the same class of drug as ranitidine.Twenty-three (11.3%) of the 203 patients also received medication from other hospital (s), although type of drugs were not known.","PeriodicalId":14621,"journal":{"name":"Japanese Journal of Hospital Pharmacy","volume":"3 1","pages":"690-695"},"PeriodicalIF":0.0,"publicationDate":"1999-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90639996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1999-01-01DOI: 10.5649/JJPHCS1975.25.138
N. Iihara, T. Tsukamoto, S. Morita
The purpose of this study is to establish the methodology of individualized medication consultation. We studied a Scale for Discriminating the Self-Regulation of Medication, which was an instrument of discriminating whether a patient was more likely to do a self-regulation of medication. Items of this scale are composed of principal factors related to self-regulation ofmedication age, degree of understanding common information for medication, and the patient's concept of what is important in taking medicines without anxiety. These items were extracted by multivariate analysis. For this analysis, we interviewed 73 patients. About 85 percent of subjects were discriminated correctly with this scale.This scale enables us: 1) to classify patients according to the discriminant values, where we can select the menu of consultation based on the classification, 2) to understand the reasons why a patient does self-regulation of medication. Consequently, it becomes easier to make an individualized medication consultation plan. To establish and validate this scale, further assessment is needed more in patients with various diseases.
{"title":"Study of a Scale for Discriminating the Self-Regulation of Medication to Select the Correct Menu of Individualized Medication Consultation.","authors":"N. Iihara, T. Tsukamoto, S. Morita","doi":"10.5649/JJPHCS1975.25.138","DOIUrl":"https://doi.org/10.5649/JJPHCS1975.25.138","url":null,"abstract":"The purpose of this study is to establish the methodology of individualized medication consultation. We studied a Scale for Discriminating the Self-Regulation of Medication, which was an instrument of discriminating whether a patient was more likely to do a self-regulation of medication. Items of this scale are composed of principal factors related to self-regulation ofmedication age, degree of understanding common information for medication, and the patient's concept of what is important in taking medicines without anxiety. These items were extracted by multivariate analysis. For this analysis, we interviewed 73 patients. About 85 percent of subjects were discriminated correctly with this scale.This scale enables us: 1) to classify patients according to the discriminant values, where we can select the menu of consultation based on the classification, 2) to understand the reasons why a patient does self-regulation of medication. Consequently, it becomes easier to make an individualized medication consultation plan. To establish and validate this scale, further assessment is needed more in patients with various diseases.","PeriodicalId":14621,"journal":{"name":"Japanese Journal of Hospital Pharmacy","volume":"53 1","pages":"138-148"},"PeriodicalIF":0.0,"publicationDate":"1999-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81234904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：